Communiqués Madrigal Pharmaceuticals, Inc.

Actions

MDGL

US5588681057

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:29:37 24/09/2026			Varia. 5j.	Varia. 1 janv.
515,86 ^USD	+0,55 %		-4,25 %	-12,13 %

23/09	Madrigal Pharmaceuticals, Inc. : Citigroup persiste à l'achat	ZM
14/09	Madrigal Pharmaceuticals, Inc. annonce l'ouverture de son nouveau siège social à Conshohocken, en Pennsylvanie	CI

Communiqués

16/09	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
02/09	Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference	AQ
20/08	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
12/08	Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors	AQ
06/08	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
06/08	Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference	AQ
30/07	Madrigal: Q2 Earnings Snapshot	AQ
30/07	Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates	AQ
21/07	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
16/07	Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026	AQ
13/07	Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio	AQ
06/07	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
22/06	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
04/06	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
03/06	Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026	AQ
27/05	Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH	AQ
21/05	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
20/05	Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk	AQ
07/05	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
06/05	Madrigal Pharmaceuticals : MDGL 1Q26 Earnings Presentation	PU
06/05	Madrigal Pharmaceuticals : 1Q26 Press Release Final	PU
06/05	Madrigal: Q1 Earnings Snapshot	AQ
06/05	Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates	AQ
05/05	Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline	AQ
22/04	Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026	AQ